…
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Income before tax | -6.07M | -3.30M | -3.10M | -5.93M | -5.41M |
| Net income | -6.21M | -3.30M | -3.10M | -5.93M | -5.74M |
| Selling general administrative | 7.13M | 2.76M | 2.64M | 5.65M | 5.52M |
| Selling and marketing expenses | - | 0.29M | 0.43M | 0.39M | 0.92M |
| Gross profit | 0.18M | 0.37M | 0.55M | 0.43M | 1.25M |
| Reconciled depreciation | 0.14M | 0.08M | 0.20M | 0.25M | 0.32M |
| Ebit | -7.12M | -2.66M | -2.55M | -5.61M | -5.19M |
| Ebitda | -6.98M | -2.57M | -2.35M | -5.36M | -4.87M |
| Depreciation and amortization | 0.14M | 0.08M | 0.20M | 0.25M | 0.32M |
| Operating income | -7.12M | -2.68M | -2.52M | -5.61M | -5.19M |
| Other operating expenses | 8.20M | 4.42M | 4.44M | 7.58M | 7.79M |
| Interest expense | 0.06M | 0.65M | 0.54M | - | 0.22M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.33M |
| Net interest income | -0.06M | -0.65M | -0.54M | -0.48M | -0.04M |
| Income tax expense | 0.13M | - | 0.00M | 0.48M | 0.33M |
| Total revenue | 1.07M | 1.74M | 1.93M | 1.97M | 2.60M |
| Total operating expenses | 7.31M | 3.05M | 3.07M | 6.03M | 6.44M |
| Cost of revenue | 0.89M | 1.37M | 1.37M | 1.55M | 1.35M |
| Total other income expense net | 1.05M | -0.62M | -0.58M | 0.15M | -0.22M |
| Net income from continuing ops | -6.21M | -3.30M | -3.10M | -5.93M | -5.74M |
| Net income applicable to common shares | - | - | - | - | -5.74M |
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Total assets | 34.75M | 21.66M | 23.13M | 29.55M | 33.55M |
| Intangible assets | 0.01M | 0.01M | 0.02M | 0.03M | 0.04M |
| Other current assets | 0.14M | 0.47M | 0.01M | 0.05M | 0.29M |
| Total liab | 5.05M | 6.22M | 9.20M | 14.86M | 17.12M |
| Total stockholder equity | 29.71M | 15.44M | 13.93M | 14.69M | 16.42M |
| Other current liab | 3.32M | 2.99M | 4.03M | 9.56M | 13.52M |
| Common stock | 64.13M | 44.53M | 4.35M | 0.91M | 0.16M |
| Capital stock | 64.13M | 44.53M | 4.35M | 0.91M | 0.16M |
| Retained earnings | -34.22M | -28.02M | -24.71M | -21.61M | -15.69M |
| Other assets | - | - | - | - | 9.46M |
| Cash | 28.18M | 18.10M | 12.07M | 17.37M | 15.52M |
| Total current liabilities | 4.35M | 6.01M | 8.90M | 14.50M | 17.12M |
| Current deferred revenue | 0.10M | 0.06M | 0.19M | 0.17M | 0.08M |
| Net debt | -27.06M | -17.12M | -9.42M | -13.61M | -13.48M |
| Short term debt | 0.42M | 0.77M | 2.35M | 3.39M | 2.05M |
| Short long term debt | 0.36M | 0.71M | 2.29M | 3.33M | 2.05M |
| Short long term debt total | 1.12M | 0.98M | 2.65M | 3.76M | 2.05M |
| Other stockholder equity | - | -0.00M | 35.32M | 35.59M | 30.99M |
| Property plant equipment | - | - | - | - | 1.59M |
| Total current assets | 34.51M | 21.30M | 14.23M | 19.52M | 22.45M |
| Net tangible assets | - | - | - | - | 16.39M |
| Short term investments | - | 0.14M | - | - | - |
| Net receivables | 3.23M | 1.90M | 1.35M | 1.58M | 5.53M |
| Long term debt | 0.64M | 0.10M | 0.12M | 0.12M | - |
| Inventory | 2.96M | 0.83M | 0.81M | 0.53M | 1.02M |
| Accounts payable | 0.50M | 1.16M | 1.28M | 1.38M | 1.48M |
| Accumulated other comprehensive income | -0.20M | -1.08M | -1.03M | -0.20M | 0.96M |
| Non currrent assets other | - | - | 8.31M | 8.74M | 9.46M |
| Non current assets total | 0.24M | 0.37M | 8.89M | 10.03M | 11.09M |
| Capital lease obligations | 0.12M | 0.18M | 0.24M | 0.31M | - |
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Investments | - | 0.06M | 0.03M | -0.01M | -0.05M |
| Change to liabilities | - | - | - | - | -0.02M |
| Total cashflows from investing activities | -1.25M | 0.06M | 0.03M | - | -0.05M |
| Net borrowings | 0.14M | -0.07M | 1.42M | - | -1.04M |
| Total cash from financing activities | 14.43M | 8.40M | -2.62M | 2.94M | 1.60M |
| Change to operating activities | - | - | - | - | 0.83M |
| Net income | -6.21M | -3.30M | -3.10M | -5.93M | -5.74M |
| Change in cash | 10.05M | 6.05M | -5.29M | 1.80M | 2.21M |
| Begin period cash flow | 18.13M | 12.08M | 17.37M | 15.57M | 13.36M |
| End period cash flow | 28.18M | 18.13M | 12.08M | 17.37M | 15.57M |
| Total cash from operating activities | -4.02M | -2.35M | -1.93M | -0.08M | 0.27M |
| Issuance of capital stock | 14.29M | 2.76M | 0.00M | 2.19M | 3.12M |
| Depreciation | 0.14M | 0.08M | 0.20M | 0.25M | 0.32M |
| Other cashflows from investing activities | - | 0.07M | 0.03M | - | 0.02M |
| Change to inventory | -0.51M | -0.01M | -0.19M | 0.41M | -0.18M |
| Change to account receivables | -1.32M | -0.48M | -0.32M | 0.91M | 0.83M |
| Other cashflows from financing activities | - | 5.70M | -3.93M | 0.77M | -1.49M |
| Change to netincome | - | - | - | - | 3.75M |
| Capital expenditures | 0.00M | 0.00M | 0.01M | 0.07M | 0.06M |
| Change in working capital | -2.39M | -0.97M | -0.38M | 1.42M | 1.90M |
| Stock based compensation | 5.31M | 0.00M | 0.35M | 0.55M | 2.33M |
| Other non cash items | 4.43M | 1.85M | 1.00M | 0.41M | 1.12M |
| Free cash flow | -4.02M | -2.35M | -1.94M | -0.15M | 0.21M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SXTC China SXT Pharmaceuticals Inc |
0.06 2.12% |
2.65 | - | - | 2.74 | 0.12 | 43.06 | 7.08 |
| MKKGY Merck KGaA ADR |
-0.68 2.09% |
31.83 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
163.45 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.38 1.77% |
21.79 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
43.05 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.
| Name | Title | Year Born |
|---|---|---|
| Mr. Feng Zhou | Chairman & CEO | 1992 |
| Mr. Xiaodong Pan | Chief Financial Officer | 1978 |
| Mr. Jun Zheng | Exec. Director | 1978 |
| Mr. Feng Zhou | Chairman of the Board & CEO | 1992 |
| Mr. Jun Zheng | Executive Director | 1978 |
| Mr. Feng Zhou | Chairman of the Board & Co-CEO | 1992 |
| Mr. Sze Beng Lim | Co-Chief Executive Officer | 1977 |
| Mr. Xiaodong Pan | Chief Financial Officer | 1977 |
| Mr. Jun Zheng | Executive Director | 1976 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.